BL
RVNC

BFSG LLC’s Revance Therapeutics, Inc. RVNC Stock Holding History

BFSG LLC’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,699
Closed -$763K – 220
2023
Q1 		$763K Sell
23,699
-44,094
-65% -$1.37M 0.14% 151
2022
Q4 		$1.25M Buy
+67,793
New +$1.55M 0.25% 108

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFSG LLC's RVNC Position: Q2 2023 in Review

BFSG LLC sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 23,699 shares — an estimated $763K sold.

BFSG LLC first reported a position in RVNC in Q4 2022 and held it in 2 quarters. The position peaked at $1.25M in Q4 2022. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • BFSG LLC reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • BFSG LLC sold 23,699 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $763K.
  • BFSG LLC first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 2 quarters.
  • BFSG LLC's Revance Therapeutics, Inc. position peaked at $1.25M in Q4 2022.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on BFSG LLC's 13F filing for Q2 2023, filed 7 Aug 2023.